XB-002 is under clinical development by Exelixis and currently in Phase I for Colorectal Cancer. According to GlobalData, Phase I drugs for Colorectal Cancer have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how XB-002’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

XB-002 overview

XB-002 is under development for the treatment of solid tumors including peritoneal cancer, fallopian tube cancer, non-small cell lung cancer, epithelial ovarian cancer, cervical cancer, pancreatic cancer, urothelial cancer including renal pelvis, ureter, urinary bladder cancer, urethral cancer and head and neck cancer squamous cell carcinoma esophageal, metastatic castrate resistant prostate cancer (mCRPC), triple negative breast cancer (TNBC), colorectal cancer, human epidermal growth factor receptor 2 negative breast cancer. It is developed based on ZymeLink technology. The drug candidate is a second generation antibody drug conjugate. It acts by targeting the tissue factor (TF). It is administered through intravenous route.

Exelixis overview

Exelixis is a biopharmaceutical company that focuses on the development and commercialization of small molecule therapies for the treatment of cancer. The company’s marketed products include, Cometriq (cabozantinib), an inhibitor of multiple receptor tyrosine kinases; Cabometyx (cabozantinib) developed for the treatment of patients with advanced renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC). The company’s pipeline product candidates include XL092 for the treatment of advanced solid malignancies and XL888, an ATP-competitive inhibitor of HSP90, and others. The company has collaborative partnerships with biopharmaceutical companies to advance the development of potential therapies for cancer and other serious diseases. Exelixis is headquartered in Alameda, California, the US.

For a complete picture of XB-002’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.